Impact of oxaliplatin-induced neuropathy: a patient perspective (Q50956973)

26 March 2018

title

Impact of oxaliplatin-induced neuropathy: a patient perspective (English)

1 reference

26 March 2018

1 reference

1 reference

5

Matthew C Kiernan

1 reference

26 March 2018

Barbara K Bennett

1

1 reference

26 March 2018

Susanna B Park

2

1 reference

26 March 2018

Cindy S-Y Lin

3

1 reference

26 March 2018

Michael L Friedlander

4

1 reference

26 March 2018

David Goldstein

6

1 reference

26 March 2018

language of work or name

English

0 references

publication date

17 March 2012

1 reference

26 March 2018

Supportive Care in Cancer

published in

1 reference

26 March 2018

volume

20

1 reference

26 March 2018

issue

11

1 reference

26 March 2018

page(s)

2959-2967

1 reference

26 March 2018

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Neurologic toxicities of cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Cancer survival in five continents: a worldwide population-based study (CONCORD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Oxaliplatin-associated neuropathy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Oxaliplatin-safety profile: neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

A review on oxaliplatin-induced peripheral nerve damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Grading of chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Rigour and qualitative research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Assessment of cancer-related neuropathy and neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Background noise: the experience of chemotherapy-induced peripheral neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Surviving Chemotherapy for Colon Cancer and Living with the Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Patient perceptions associated with chemotherapy-induced peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Persistent mobility disability after neurotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

The GRID-HAMD: standardization of the Hamilton Depression Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1428-5

Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement

21 January 2018

1 reference

12 December 2020

Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up

1 reference

12 December 2020

Pharmacokinetics and safety profile of oxaliplatin

1 reference

12 December 2020

Short- and long-term impact of receiving genetic mutation results in women at increased risk for hereditary breast cancer

1 reference

12 December 2020

Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07

1 reference

12 December 2020

10.1007/S00520-012-1428-5

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018